Hypothetical lifetime economic burden of Pelvic Floor Dysfunction in a female patient: Impact of very early diagnosis using 3D Dynamic Pelvic Floor Ultrasound with Tomographic Ultrasound Imaging (TUI).
Embedded Files
Manuscript Type: A Literature-Based Case Study. Hypothetical analysis.
Authors: Novasono Corporation (original multi-study synthesis by Felix J. Martin. Isac Cabrera. Tatiana Pupo)
Date: January 2026
Funding / Conflicts of Interest: None declared
ABSTRACT
ABSTRACT
Pelvic floor dysfunction (PFD) imposes substantial lifetime costs on affected women. Using a hypothetical case modeled on peer-reviewed literature, we compare the incremental lifetime economic burden (direct medical, routine supplies, and indirect productivity losses) in a U.S. female patient under two scenarios: (1) standard late diagnosis at age 48 and (2) very early postpartum/antenatal diagnosis via 3D/4D dynamic translabial pelvic floor ultrasound combined with tomographic ultrasound imaging (TUI). Early detection of levator ani muscle (LAM) micro-trauma, pelvic floor dyssynergia, early urethral funneling, and subtle pelvic organ prolapse (POP) indicators, followed by targeted ultrasound-guided biofeedback pelvic floor muscle training (PFMT), is projected to reduce the burden by 60–80% (from ~$75,000–$125,000 to ~$15,000–$40,000 in 2025–2026 USD). These estimates are supported by claims data on urinary incontinence (UI) lifetime costs and recent analyses of chronic pelvic pain/PFD utilization. Early 3D/TUI imaging enables precise risk stratification and prevention, offering a cost-dominant strategy.
Keywords: Pelvic floor dysfunction; 3D/4D ultrasound; tomographic ultrasound imaging; lifetime economic burden; pelvic floor muscle training; biofeedback; postpartum prevention.
INTRODUCTION
INTRODUCTION
Pelvic floor dysfunction (PFD), encompassing stress/mixed urinary incontinence (UI), pelvic organ prolapse (POP), dyssynergia, and related chronic pelvic pain, affects 25–33% of adult women and carries a lifetime surgery risk of approximately 20% by age 80. These conditions arise commonly from vaginal delivery, aging, and menopause, leading to chronic direct medical costs (diagnostics, therapy, surgery), routine out-of-pocket expenses (pads, laundry), and indirect burdens (lost productivity).
A landmark claims-based analysis reported incremental lifetime medical costs for stress UI alone at $58,000 per woman (2002 USD), with total lifetime costs 1.8 times higher than controls; annual direct costs averaged $5,642 and indirect workplace costs $4,208 (1998 data). More recent data on treated chronic pelvic pain/PFD patients (overlapping with PFD) show an average per-patient burden of $29,951, including $15,750 in surgeries, $5,264 in diagnostics, and $8,937 in pelvic floor physical therapy (PT). Untreated or delayed PFD can approach $30,000 per individual in medical and productivity losses.
3D/4D dynamic translabial/transperineal pelvic floor ultrasound with TUI has emerged as a non-invasive, office-based, low-cost alternative to MRI and others diagnostic alternatives for early detection. It reliably visualizes LAM integrity, hiatal ballooning, dyssynergia (paradoxical contraction/poor relaxation), early urethral funneling (bladder neck metrics), and subtle POP changes in real time during rest, contraction, and Valsalva. TUI provides multi-slice axial views (2.5 mm intervals) by ultrasound comparable to MRI for avulsion diagnosis but with better resolution and dynamic. When combined with visual biofeedback PFMT, it improves muscle coordination, adherence, and long-term outcomes, preventing progression in postpartum women.
This literature-based hypothetical case study quantifies the potential lifetime economic impact of integrating very early 3D/TUI screening versus standard care.
METHODS. Hypothetical patient case and cost modeling.
METHODS. Hypothetical patient case and cost modeling.
Patient Profile (“Patient A”): A representative U.S. woman (Miami, FL) with first vaginal delivery at age ~32 and average female life expectancy (~82 years). Incremental PFD-attributable costs only (2025–2026 USD, inflation-adjusted from source data using approximate CPI factors). Assumptions are conservative, literature-derived, and identical across scenarios except for timing and intervention.
-Base Scenario (late diagnosis at age 48): Moderate stress/mixed UI + mild POP; 34-year horizon; conservative management + possible surgery.
-Early Diagnosis Scenario (very early 3D/TUI at 6–12 weeks postpartum or antenatally): Subclinical LAM micro-trauma, dyssynergia, early funneling, and stage 0–I POP detected; immediate 1 short course (6–12 sessions) of ultrasound-guided biofeedback PFMT; maintenance home exercises; 50-year horizon with near-complete prevention.
Costs aggregated from:
-Birnbaum et al. (direct/indirect UI lifetime and annual figures).
-Hutton et al. (cumulative PFD/CPP utilization).
-Systematic reviews on postpartum PFMT and ultrasound biofeedback efficacy/prevention.Scan cost: $300–$600 (Miami-area 3D/TUI estimate). Sensitivity ranges reflect severity and adherence variations.
Results
Results
Base Scenario Lifetime Burden (incremental, 2025–2026 USD):
-Direct medical: $35,000–$55,000
-Routine supplies/self-care: $25,000–$40,000
-Indirect (productivity): $15,000–$30,000 Grand total: $75,000–$125,000 (midpoint ~$100,000).
Very Early 3D/TUI Scenario Lifetime Burden:
-Direct medical (1–2 scans + short biofeedback PFMT): $3,000–$10,000
-Routine supplies (70–90% lower): $3,000–$10,000
-Indirect (minimal/none): $2,000–$8,000 Grand total: $15,000–$40,000 (midpoint ~$25,000–$30,000).
Projected Savings: 60–80% reduction (~$50,000–$90,000 per patient).
Table 1. Side-by-Side Comparison (Same Patient, 2025–2026 USD, Incremental Costs)
Category Base Scenario (Diagnosis at Age 48) Very Early 3D/TUI Scenario (Postpartum ~32) Key Literature Support for Difference
Direct Medical $35,000–$55,000 $3,000–$10,000 Avoids surgery ($10k–$19k+) & repeated
diagnostics (Hutton et al.)
Routine Supplies $25,000–$40,000 $3,000–$10,000 70–90% reduction via prevented progression (Romeikienė et al.)
Indirect Productivity $15,000–$30,000 $2,000–$8,000 Early biofeedback minimizes impairment
(Birnbaum et al.)
Grand Total $75,000–$125,000 $15,000–$40,000 60–80% savings; aligns with prevention
data
Discussion
Discussion
The modeled 60–80% lifetime cost reduction with very early 3D/TUI is plausible given the prognostic and therapeutic value of the modality. As stated by Ying et al., “3D ultrasound is an effective tool to detect the pelvic floor in POP women who presented with abnormalities in the morphology and structure of pelvic floor.” TUI enables reliable diagnosis of LAM avulsion and dyssynergia, while dynamic imaging quantifies funneling and hiatal ballooning—features often missed on clinical exam alone.
Literature confirms that real-time ultrasound visual biofeedback enhances PFMT adherence and prevents PFD progression in postpartum cohorts. Systematic reviews demonstrate PFMT’s protective effect when initiated early, reducing long-term UI and POP risk without adverse effects.
Cost data reinforce the economic rationale: delayed care drives fragmented high-cost utilization (Hutton et al.), whereas prevention via accessible imaging avoids surgery and chronic supplies. Limitations include the hypothetical nature (no single lifetime model with exact 3D/TUI protocol exists) and U.S.-centric data; real-world savings may vary by insurance and access. Nonetheless, the approach aligns with calls for non-invasive early screening in high-risk women.
CONCLUSION
CONCLUSION
Very early diagnosis of LAM defects, dyssynergia, funneling, and early POP via 3D dynamic pelvic floor ultrasound with TUI, followed by biofeedback PFMT, can reduce the hypothetical lifetime PFD burden for one female patient from $75,000–$125,000 to $15,000–$40,000—a clinically and economically meaningful improvement. This low-cost, patient-friendly technology supports guideline-aligned prevention and should be considered for routine or risk-based postpartum/antenatal implementation to mitigate individual and societal burdens
REFERENCES (selected):
REFERENCES (selected):
-Birnbaum HG, et al. Lifetime medical costs for women: cardiovascular disease, diabetes, and stress urinary incontinence. Women’s Health Issues. 2003;13(6):204-213.
-Hutton D, et al. The burden of Chronic Pelvic Pain (CPP): Costs and quality of life... PLoS One. 2023;18(2):e0269828.
-Ying T, et al. Three-dimensional Ultrasound Appearance of Pelvic Floor in Women with Pelvic Organ Prolapse. J Obstet Gynaecol Res. 2012
(PMC3498754)
Page updated
Google Sites
Report abuse